When, 25 years ago, a team of psychiatrists from Yale University tested the intravenous anaesthetic ketamine on patients with depression, they didn't realize that they were about to make what has been called the "biggest breakthrough in depression research in the last 50 years".
Three decisive discoveries
The impact of this discovery is underpinned by three central findings that have changed the way we understand and treat the disease:
-
Fast-acting and effective
Unlike traditional oral antidepressants, which can take weeks to show results, ketamine has shown the ability to improve depressive symptoms in just a few hours. This speed represents a radical change in crisis management, especially in severe cases. -
A new mechanism of action
Until now, the dominant theory - the monoaminergic hypothesis - attributed the effect of antidepressants to the modulation of neurotransmitters such as serotonin, noradrenaline and dopamine. Ketamine, however, acts differently, interfering with glutamatergic signaling and inhibiting N-methyl-D-aspartate (NMDA) receptors. This alternative pathway has opened up new perspectives for drug development. -
Efficacy in treatment-resistant depression (TRD)
Ketamine showed benefits even in patients who did not respond to conventional antidepressants - a group that accounts for around 25% of all cases of depression.
Conclusion
The discovery of ketamine's antidepressant potential not only expanded treatment options, but also challenged and renewed the theoretical foundations of psychiatry. Today, its use is seen as one of the most promising strategies for tackling one of today's biggest mental health problems.
Check out our Psychedelic-Assisted Psychotherapy programs here.
